SM 04554

Drug Profile

SM 04554

Alternative Names: SM-04554

Latest Information Update: 21 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Samumed
  • Class Skin disorder therapies; Small molecules
  • Mechanism of Action Wnt signalling pathway modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alopecia

Most Recent Events

  • 21 Mar 2017 Clinical development is ongoing in USA and Australia (Topical)
  • 06 Mar 2017 Efficacy and adverse event data from a phase II trial in presented at the 75th American Academy of Dermatology (AAD-2017)
  • 01 Apr 2016 Samumed completes a phase II trial for Alopecia in USA (NCT02503137)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top